VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence

Pharmacogenomics. 2019 Apr;20(5):331-341. doi: 10.2217/pgs-2018-0137. Epub 2019 Apr 15.

Abstract

Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction. Subjects & methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-assisted treatment, 163 opioid-exposed but not opioid-dependent volunteers who have been using illicit opioids but never became opioid-dependent and 153 healthy controls. Results: Nominal associations were indicated for 20 variants in six genes including an experiment-wise significant association from the combined effect of three SLC18A2 SNPs (rs363332, rs363334 and rs363338) with heroin dependence (pfinal = 0.047). Conclusion: Further studies are warranted to confirm and elucidate the role of these variants in the vulnerability to opioid addiction.

Keywords: VMAT2; association study; case–control; exposed but not dependent; heroin dependence.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid / administration & dosage
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease
  • Heroin Dependence / drug therapy
  • Heroin Dependence / genetics
  • Humans
  • Male
  • Methadone / therapeutic use
  • Middle Aged
  • Netherlands
  • Opiate Substitution Treatment
  • Opioid-Related Disorders / drug therapy
  • Opioid-Related Disorders / genetics*
  • Pharmacogenomic Testing
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • Vesicular Monoamine Transport Proteins / genetics*
  • White People / genetics

Substances

  • Analgesics, Opioid
  • SLC18A2 protein, human
  • Vesicular Monoamine Transport Proteins
  • Methadone